Stock chart
Analyses on Teuza (4)
- March 26, 2026March 26, 2026
- Follow-up
Teuza: Nano Cell Is No Longer a Footnote, and the Question Is Whether It Is an Asset or a Funding Line
Nano Cell has already become Teuza's second anchor holding, but as of year-end 2025 it still looks less like an asset that is beginning to fund itself and more like a position whose value still leans on follow-on rounds.
- Follow-up
Teuza: Why 3% in Tyto Is Worth Far Less than 3% of Company Value
The 3% Tyto headline is misleading because it skips three critical layers: full dilution, a deep rights hierarchy across the cap table, and an OPM framework that allocates value as an option on a future liquidity event. That is why Teuza's holding stops at $2.951 million, far be…
- Follow-up
Teuza: The Alfred Mann Buyback, the Capital Reduction, and the Real Cost to Cash
The Alfred Mann settlement is no longer background legal noise but a liquidity and capital-allocation test: Teuza is buying back roughly 21% of its share capital at a premium through a court-required capital reduction while the cash cushion is thin and the possible Bioness offse…
Teuza 2025: The Portfolio Still Has Value, but 2026 Will Be Decided by Cash
Teuza enters 2026 as a small public holding company with real residual value in its private portfolio, but the bottleneck has moved to accessible parent-level cash rather than paper fair value.
